Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term conformal radiotherapy. Found 11 abstracts

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Feb;64(2):518-26.
Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Mar;64(4):1140-50.
Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?. Cancer. 2005 Jul 15;104(2):299-304.
Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: An astro outcomes initiative. International Journal of Radiation Oncology Biology Physics. 2005 May;62(1):3-19.
Price RA, Paskalev K, McNeeley S, Ma CM. Elongated beamlets: a simple technique for segment and MU reduction for sMLC IMRT delivery on accelerators utilizing 5 mm leaf widths. Physics in Medicine and Biology. 2005 Oct 07;50(19):N235-N242.
Wang L, Hoban P, Paskalev K, Yang J, Li JS, Chen LL, Xiong WJ, Ma CC. Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy. MEDICAL DOSIMETRY. 2005 Jan;30(2):97-103.
Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Seminars in Radiation Oncology. 2004 Oct;14(4):280-6.
Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. International Journal of Radiation Oncology Biology Physics. 2002 Nov;54(3):677-85.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2002 Aug;53(5):1097-105.
Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. International Journal of Radiation Oncology Biology Physics. 2000 Jan 15;46(2):391-402.
Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. The Prostate. 1998 Nov;37(3):195-206.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term conformal radiotherapy

conformal radiotherapy carcinoma radiation-therapy adenocarcinoma escalation prostate cancer toxicity morbidity irradiation radical prostatectomy therapy external-beam radiotherapy Oncology dose-volume histograms radiotherapy late rectal toxicity IMRT cancer antigen nadir stereotactic radiosurgery dose-response Nuclear Medicine & Medical Imaging Radiology pretreatment nomogram control ml prostate-specific antigen prostatectomy prostate neoplasms disease-free survival dosimetry oncology group iii randomized trial induced injury alpha 70 gy systematic review radical amifostine defines disease freedom biochemical failure concurrent chemotherapy interval modulated radiation-therapy hypofractionation biochemical-evidence external beam radiotherapy less-than-or-equal-to-10 mMLC prognosis therapy oncology group multileaf collimator stage t1-t2 pelvic irradiation randomized-trial planning system localized carcinoma radiation dosimetry intensity-modulated radiotherapy dose-escalation quality assurance tumor-control PSA nadir androgen suppression follow-up radiation dose local- three-dimensional radiotherapy experience dosimetric predictors radiation therapy prostate carcinoma-treatment delay optimization beta-ratio fractionation external-beam radiation free survival constraints impact surgery clinical-trials ng radiation photons antigen imrt prostate biopsy acute toxicity rectal toxicity quality-of-life local-control prostate-specific antigen nadir 3D conformal radiation therapy leaf width volume dose miniature multileaf collimator cell lung-cancer randomized phase-iii
Last updated on Thursday, August 06, 2020